-
Mashup Score: 84Cardio-Oncology and Immunology | UCSF Cardiology - 3 month(s) agoSource: ucsfhealthcardiology.ucsf.eduCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 221New Study Looks at Why Cancer Treatments Cause Heart Damage - 4 month(s) ago
New drugs and therapies have become indispensable for treating an array of cancers. Unfortunately, they can also cause damage to the heart, a side effect that has led to the development of a new discipline in medicine, called cardio-oncology.
Source: www.ucsf.eduCategories: General Medicine News, CardiologistsTweet-
Excited to announce the funding of the first ever @NIH Program Project Grant (PPG) in Cardio-Oncology! Terrific collaboration between @UCSFCardiology & @StanfordCVI! @Joseph_C_Wu #CardioOnc https://t.co/IyMVkiFOdJ https://t.co/7u9pbrdVTL
-
-
Mashup Score: 43UCSF Cardiovascular Research Institute (CVRI) | - 4 month(s) ago
The Cardiovascular Research Institute (CVRI) performs cutting edge research illuminating causes, treatment and prevention of cardiovascular and pulmonary biology and disease and trains clinicians and scientists to become future leaders of these fields.
Source: cvri.ucsf.eduCategories: General Medicine News, CardiologistsTweet-
Excited 2 finally see this updated UCSF CVRI website! Of all the place I have been, the best place to do cardiovascular research! @BrianBlackUCSF @ZaroLab @FidlerLab @abbybuch @UCSFCardiology @Ucsf_Biochem https://t.co/AKze5N9e2W https://t.co/4jIUTtke0q
-
-
Mashup Score: 79Pericardial Disease Center | UCSF Cardiology - 6 month(s) ago
What is Pericarditis? The pericardium is a protective, fluid-filled sac that surrounds the heart. It supports proper heart function and protects the heart from infection and trauma. Pericarditis is inflammation of the pericardium. Pericarditis is characterized by chest pain with associated electrocardiographic changes and usually pericardial effusion (fluid in the pericardium).
Source: ucsfhealthcardiology.ucsf.eduCategories: General Medicine News, CardiologistsTweet-
Proud to announce the creation of the UCSF Pericarditis Center led by @baik_alan! Great addition to @UCSFCardiology Section of #CardioOnc & Immunology! Website made by @UCSFDOM PGY2 resident extraordinaire @aishwarya_nene! @Bob_Wachter @MandarArasMD https://t.co/zCdV0zOdsY
-
-
Mashup Score: 2Cardio-Oncology and Immunology Fellowship | UCSF Cardiology - 6 month(s) ago
Fellowship Mission Statement To train the next generation of leaders in cardio-oncology, including diverse academic physician-scientists who will help advance the field. We seek to assemble a class that displays diversity in background and thought, strong intellect, and the potential to improve patients’ lives through innovation in research, clinical care, and education.
Source: ucsfhealthcardiology.ucsf.eduCategories: General Medicine News, CardiologistsTweet-
For more information for Fellowship options @UCSFCardiology see below: https://t.co/5WO4aRtB0w.
-
-
Mashup Score: 117Cardio-Oncology: A New Clinical Frontier and Novel Platform for Cardiovascular Investigation | Circulation - 7 month(s) ago
In the past 20 years, cardio-oncology has emerged as a new cardiovascular subspeciality. Older, nonspecific chemotherapies (such as anthracyclines) and radiation had been well-described cardiotoxic agents, with anthracycline-associated heart failure initially extensively studied in the pediatric population by Drs Steven Lipshultz (a cardiologist) and Stephen Sallan (an oncologist). The hope was that with the emergence of novel targeted therapies, these toxicities would be curtailed. However, > 20 years
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet-
Proud 2 present this vision for #CardioOnc in @CircAHA as part of @American_Heart centennial collection! Cardio-Oncology: A New Clinical Frontier and Novel Platform for Cardiovascular Investigation | Circulation https://t.co/VsK3vSSTtQ
-
-
Mashup Score: 107Cardio-Oncology: A New Clinical Frontier and Novel Platform for Cardiovascular Investigation | Circulation - 7 month(s) ago
In the past 20 years, cardio-oncology has emerged as a new cardiovascular subspeciality. Older, nonspecific chemotherapies (such as anthracyclines) and radiation had been well-described cardiotoxic agents, with anthracycline-associated heart failure initially extensively studied in the pediatric population by Drs Steven Lipshultz (a cardiologist) and Stephen Sallan (an oncologist). The hope was that with the emergence of novel targeted therapies, these toxicities would be curtailed. However, > 20 years
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet-
Proud 2 present this vision for #CardioOnc in @CircAHA as part of @American_Heart centennial collection! Cardio-Oncology: A New Clinical Frontier and Novel Platform for Cardiovascular Investigation | Circulation https://t.co/VsK3vSSTtQ
-
-
Mashup Score: 74Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade—a worldwide perspective - 11 month(s) ago
This up-to-date comprehensive worldwide pharmacovigilance study defines the spectrum, characteristics, and evolution of irAE reporting summarizing over a decade of use. Multiple risk factors and clinical peculiarities for specific irAE have been identified as signals to guide clinical practice and future research.
Source: www.thelancet.comCategories: General Medicine News, CardiologistsTweet-
Another masterpiece by @DrJESalem & team. Full spectrum of irAE w/ ICI treatment! New insights w/ myocarditis, myositis, MG (overlap syndrome). Shortest duration from initial exposure (31-33 days) & highest mortality (27.6%) @TheLancet @eClinicalMed https://t.co/sQXaihOXgc
-
-
Mashup Score: 58B-Cell Immune Checkpoints Come of Age in Cardio-oncology - 11 month(s) ago
Section of Cardio-Oncology and Immunology, Cardiovascular Research Institute (CVRI), University of California San Francisco, School of Medicine (A.G., J.M.). Yale University School of Medicine, New Haven, CT (A.G.). Correspondance to: Javid J. Moslehi, MD, Section of Cardio-Oncology and Immunology, Cardiovascular Research Institute (CVRI), University of California San Francisco, School of Medicine, 555 Mission Bay Blvd. S., Room 452V San Francisco, CA 94143-3118. Email: Section of Cardio-Oncology and
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet-
Congrats 2 @SarnoffCardio Fellow Alan Gutierrez on this @CircRes Editorial! Immune Checkpoints (IC) go beyond T cell ones (CTLA-4, PD-1). The #MoslehiLab has several projects focused on these new IC! Ping me if you want to learn more! @UCSFCardiology https://t.co/4O90p9u1un https://t.co/QqN06RZawU
-
-
Mashup Score: 74Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade—a worldwide perspective - 11 month(s) ago
This up-to-date comprehensive worldwide pharmacovigilance study defines the spectrum, characteristics, and evolution of irAE reporting summarizing over a decade of use. Multiple risk factors and clinical peculiarities for specific irAE have been identified as signals to guide clinical practice and future research.
Source: www.thelancet.comCategories: General Medicine News, CardiologistsTweet-
Another masterpiece by @DrJESalem & team. Full spectrum of irAE w/ ICI treatment! New insights w/ myocarditis, myositis, MG (overlap syndrome). Shortest duration from initial exposure (31-33 days) & highest mortality (27.6%) @TheLancet @eClinicalMed https://t.co/sQXaihOXgc
-
Excited 2 see the pieces coming together for our #CardioImmunology program at UCSF, including dedicated myocarditis, pericarditis & CHIP clinics + our #CardioOnc program (w/ immunotoxicity). Basic/translational research programs complement! https://t.co/8XBT4C8oC4 https://t.co/Stixj9xtO4